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Background: There are currently no reliable predictive factors for gastric cancer recurrence. The aim of this study
was to evaluate the relationship between bcl-2 expression and risk of gastric cancer recurrence.
Methods: From January 1996 to December 2007, 449 gastric cancer patients who underwent curative resection
were retrospectively studied. The expression levels of bcl-2 were examined by immunohistochemistry. Logistic
regression was performed to identify independent risk factors for overall recurrence of gastric cancer.
Results: 151 patients (33.6%) experienced recurrences. The median time to recurrence was 17.0 months, 113
(74.8%) patients had recurrences within 2 years. Peritoneal recurrence was the most prevalent pattern, followed by
hematogenous metastasis in which the liver was the most common site. Depth of invasion, lymph node
metastases, and negative expression of bcl-2 were independent risk factors for overall recurrence. The overall
survival time of recurrent patients was 22.7 months. The median survival time after recurrence was 6.7 months.
Conclusion: The depth of invasion, lymph node metastases and expression of bcl-2 are independent factors for
predicting gastric cancer recurrence.
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Although the incidence of gastric cancer has been declin-
ing substantially for several decades, it is still the fourth
most common cancer and the second most frequent cause
of cancer death [1,2]. Although the majority of patients
with early-stage gastric cancer can have long survival
times after surgery, approximately 40% of patients die
from recurrence, even after undergoing curative surgery
[3]. The presence or absence of recurrence is widely con-
sidered to be the most important predictor for survival, as
the prognosis for patients with recurrence is extremely
dismal. Therefore, it is very important to precisely predict
the risk of recurrence at an early stage in order to improve
prognosis of patients with recurrence. However, it has
been demonstrated that routine followup after surgery for* Correspondence: wangyn1111@hotmail.com
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unless otherwise stated.gastric cancer is not helpful in detecting recurrence at
an early stage [4]. Therefore, it is essential to investigate
specific factors that can identify subgroups of patients
with more aggressive disease. Recently, some studies have
shown that pathological factors such as lymph node sta-
tus, depth of invasion, and tumor size, play a crucial role
in predicting recurrence after gastrectomy [5,6]. However,
it is difficult to predict recurrence using common clinico-
pathological factors. Given that some biological markers,
such as oncogenes, tumor-suppressor genes, cell-cycle
regulators, and DNA repair genes, are related to tumor
genesis, growth, invasion and metastasis, many investiga-
tors are searching for new predictive factors among these
molecular markers. In a previous study, we evaluated the
prognostic value of biological markers such as p53, bcl-2,
bax, and c-myc in gastric cancer, and found that bcl-2 was
significantly associated with prognosis in gastric cancer
patients [7]. Therefore, we hypothesized that bcl-2 expres-
sion may reflect tumor characteristics, and thus, serve as a
reliable indicator for predicting recurrence. The objective. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion can predict disease recurrence after curative resection
in patients with gastric cancer.
Methods
Patients
Between January 1996 and December 2007, 4,426 patients
with histologically confirmed primary gastric adenocarcin-
oma underwent gastrectomy at the Department of Gastric
Cancer and Soft Tissue Sarcoma in Fudan University
Shanghai Cancer Center. Out of these patients, 449 cases
were selected. These patients’ specimens were stained
immunohistochemically. Data were retrieved from pa-
tients’ operative and pathological reports. Follow-up
data were obtained by phone, letter, and the outpatient
clinical database. Staging was performed according to the
Union for International Cancer Control (UICC) TNM
Staging Classification for Carcinoma of the Stomach
(Seventh Edition, 2010) [8]. A followup of all patients
was carried out according to our standard protocol
(every three months for at least 2 years, every 6 months for
the next 3 years, and after 5 years every 12 months for life).
The check-up items included physical examination, tumor-
marker examination, ultrasound, chest radiography, com-
puted tomographic scan, and endoscopic examination. The
range of the followup was from January 1996 to May 2010.
The median follow-up time was 76.5 months at the time of
analysis. Written informed consent had been obtained from
all the patients, and this study was approved by the Ethical
Committee of Shanghai Cancer Center of Fudan University.
The study was retrospective.
Immunohistochemical staining
Bcl-2 was detected by the immunohistochemical method.
Antibodies were purchased from Dako (Hamburg, Germany).
Immunohistochemical staining was performed by the
enhanced labeled polymer system method. Paraffin
sections were deparaffinised with xylene and hydrated
with ethanol/deionized water. Sections were then incubated
with methanol/0.3% H2O2 and blocked with non-specific
staining blocking reagent. After overnight incubation at 4°C
with anti-bcl-2 antibody (diluted 1:100), sections were
treated according to standard immunoperoxidase methods.
Negative control sections were subjected to the same
procedure, except that the first antibody was replaced
by PBS. No positive staining was observed in the controls.
The location of staining for bcl-2 was predominantly in
cytoplasm and cytomembrane.
Immunohistochemical staining: scoring
All slices were independently evaluated by two pathologists.
The percentage of immunoreactive cells and staining inten-
sities were evaluated. The percentage of immunoreactive
cells was graded on a scale of 0 to 4: no staining was scoredas 0, 1 to 10% of cells stained scored as 1, 11 to 50% as 2,
51 to 80% as 3, and 81 to 100% as 4. The staining intensities
were graded from 0 to 3: 0 was defined as negative, 1 as
weak, 2 as moderate, and 3 as strong, respectively. The raw
data were converted to an immunohistochemical score
(IHS) by multiplying the quantity and intensity scores.
An IHS score of 9 to 12 was considered as strong im-
munoreactivity (+++), 5 to 8 as moderate (++), 1 to 4
as weak (+), and 0 as negative (-). Cases with a score of
less than 1 were considered as negative, and those with ≥1
were regarded as positive [9].
Statistical analysis
Data were presented as the mean ± SD or the median for
numeric parameters. The patients’ features and clinical
characteristics were analyzed using the two-tailed Student
t-test or Pearson chi-square test as appropriate. Factors that
were deemed of potential importance on univariate analysis
were included in the multivariate analysis. Logistic regres-
sion was used to estimate related factors for recurrence.
The accepted level of significance was P < 0.05. Statistical
analyses and graphics were performed using the SPSS 13.0
statistical package (SPSS, Inc., Chicago, IL, USA).
Results
Clinicopathological characteristics
The study included 307 male and 142 female patients
(2.2:1) with a mean age of 57 years. There were 49 (10.9%)
early gastric cancers and 400 (89.1%) advanced gastric
cancers. According to histological type, well-differentiated
tumors were observed in 7 (1.5%) patients, moderately-
differentiated in 149 (33.2%) patients, and poorlydifferen-
tiated tumors in the remaining 293 (65.3%) patients.
According to Borrmann type, 49 (10.9%) were type 0, 32
(7.1%) type I, 14 (3.1%) type II, 333 (74.2%) type III, and 21
(4.7%) type IV. Of these patients, 147 (32.7%) had tumors
located in the upper third of the stomach, 65 (14.5%) had
tumors in the middle third, 212 (47.2%) had tumors in the
lower third, and 25 (5.6%) had tumors occupying two-
thirds or more of the stomach. Lymph node metastasis
was observed in 326 patients, and the metastasis rate was
72.6%. The distribution of pathological stage was as follows:
35 (7.8%) patients belonged to stage IA, 34 (7.6%) IB, 50
(11.1%) IIA, 75 (16.7%) IIB, 82 (18.3%) IIIA, 80 (17.8%) IIIB,
and 93 (20.7%) IIIC.
Expression of bcl-2
Bcl-2 expression was positive in 21.2% of all gastric can-
cer tissues. Bcl-2 staining was observed in the cytoplasm
and cytomembrane of carcinoma cells (Figure 1). Bcl-2
expression was associated with pathological stage. There
was no correlation between bcl-2 and other patho-
logical parameters, such as age, gender, histological type,
Borrmann type, tumor location, or tumor size.
Figure 1 Positive expression of bcl-2 immunohistochemistry in gastric cancer tissue. A original magnification ×100, B original magnification ×400.
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Recurrence occurred in 151 (33.6%) patients during the
follow-up period. The median time to recurrence was
17.0 months (range from 2.0 to 91.0 months), and the mean
time was 21.1 months. Among patients with recurrence,
113 (74.8%) had recurrence within 2 years. The frequency
and rate of recurrence are demonstrated in Figure 2.
Of the 151 patients with recurrence, 58 (38.4%) were
diagnosed with peritoneal recurrence, which was the
most prevalent, 49 (32.5%) patients had hematogenous
metastases, which was the second most common recur-
rence pattern, and liver was the most frequently involved
organ; it was implicated in 57.1% of all recurrent patients.
Other recurrences were loco-regional (n = 34, 22.5%), dis-
tant lymph node metastases (n = 8, 5.3%), or at multiple
sites (n = 2, 1.3%) (Figure 3).Figure 2 Frequency of recurrence after curative operation by year.Recurrence-related factors
Univariate analysis showed that Borrmann type, depth of
invasion, lymph node status, and expression of bcl-2 were
associated with overall recurrence, whereas age, gender,
histological type, tumor location, and tumor size were not
(Table 1). Logistic regression was employed to identify the
independent risk factors for overall recurrence. It was
demonstrated that depth of invasion, lymph node metas-
tases, and negative expression of bcl-2 were independent
predictive factors for overall recurrence (Table 2).
Univariate analysis showed that Borrmann type, depth of
invasion, lymph node status, histology, gender, and expres-
sion of bcl-2 were associated with peritoneal recurrence.
Logistic regression showed that depth of invasion, lymph
node status, histology, and bcl-2 were independent predict-
ive factors for peritoneal recurrence. Tumor location and
Borrmann type were related to hematogenous metastases,
and tumor location was the only independent predictive
factor. There was no correlation between clinicopathological
parameters and loco-regional recurrence.Figure 3 Pattern of recurrence of after curative gastrectomy.
Table 1 Univariate analysis of risk factors for recurrence in gastric cancer
No recurrence Recurrence P-value
(n = 298) (n = 151)
Age (years), mean ± SD 57.8 ± 11.9 55.8 ± 12.9 0.095
Gender, male/female 203/95 104/47 0.871
Tumor size (cm), mean ± SD 4.8 ± 2.5 5.3 ± 2.7 0.054
Tumor location, upper/middle/lower/two or more 91/38/153/16 56/27/59/9 0.094
Borrmann type, 0/I/II/III/IV 45/22/9/211/11 4/10/5/122/10 0.002
Histology, well/moderate/poorly differentiated 5/101/192 2/48/101 0.899
Depth of invasion, T1 + T2/T3 + T4 94/204 16/135 0.000
Lymph node status, negative/positive 108/190 15/136 0.000
Bcl-2, negative/positive 226/72 128/23 0.029
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The overall 5-year survival rate was 52% for all patients.
Five-year survival rate was 58.9% and 45.5% in bcl-2
positive and bcl-2 negative patients respectively. In bcl-2
positive patients, pathological stage and tumor location
significantly affected prognosis, and pathological stage
was an independent prognostic factor. In bcl-2 negative
patients, univariate analysis showed that Borrmann type,
depth of invasion, lymph node metastases, tumor size,
tumor location and pathological stage significantly affected
prognosis. Multivariate analysis showed that lymph node
metastases, tumor location, and pathological stage were
independent prognostic factors.
The median survival time of patients with recurrence
was 22.7 months. The median survival time after recurrence
was 6.7 months. According to the different recurrence pat-
terns, the median survival time after peritoneal recurrence,
hematogenous metastases, loco-regional recurrence,
and distant lymph node metastases were 5.7 months
(2.6 to 12.4), 7.3 months (2.4 to 11.7), 7.0 months (2.5 to
17.1), and 6.1 months (3.9 to 7.9), respectively. Patients with
peritoneal and distant lymph node recurrence had a shorter
survival time; however this was not statistically significant.
Discussion
The main findings of this study were that (1) peritoneal
recurrence was the most prevalent recurrence pattern after
curative surgery, and (2) the depth of invasion, lymph nodeTable 2 Multivariate analysisof risk factors for recurrence
in gastric cancer
Variable P-value Odds ratio 95% CI
Age 0.116 0.710 0.463, 1.088
Gender 0.775 1.069 0.677, 1.687
Borrmann type 0.334 0.872 0.660, 1.152
Depth of invasion 0.017 0.438 0.222, 0.861
Lymph node status 0.000 3.753 2.040, 6.905
Bcl-2 0.047 0.577 0.336, 0.992metastases and negative expression of bcl-2 were independ-
ent risk factors for overall recurrence.
Gastric cancer is one of the most common malignancies
worldwide. Although the prognosis of patients with gastric
cancer has improved as a result of better diagnostic tech-
niques and therapeutic strategies, gastric cancer is still
the second leading cause of cancer-related deaths [2]. The
dismal prognosis of gastric cancer is due principally to the
frequency of recurrence and metastasis. Therefore, it is
very important to clarify the pattern of recurrence and the
risk factors for recurrence, which can contribute to the
conduct of postoperative clinical practice and followup.
In our study, 151 (33.6%) patients had recurrence during
the follow-up period. The mean time to recurrence was
21.1 months; 113 patients (74.8%) had recurrence within
2 years. This result shows that most gastric cancer recur-
rence occurs within 2 years, and is consistent with other
studies [10-12]. Yoo et al. [12] reported 508 patients with
recurrence after curative resection for gastric cancer and
showed that the mean length of time to recurrence was
21.8 months. Therefore, it was necessary to reinforce the
followup within 2 years after curative resection.
It has been reported that the most common recurrence
patterns are hematogenous recurrence and peritoneal
dissemination in gastric cancer [3,12-14]. In our series,
peritoneal recurrence was the most common pattern,
accounting for 38.4% of all patients with recurrence,
followed by hematogenous metastases (32.5%). Our results
are consistent with previous studies [3,12]. Maehara et al.
reported [15] that the peritoneal pattern accounted for
50% of cases, hematogenous recurrence for 40% of cases,
and loco-regional recurrence for 20%. However, there are
still some disputes. An Italian study showed that the most
common recurrence pattern was loco-regional, accounting
for 45% of all recurrent cases [16]. This disparity indicated
that there are some differences in recurrence patterns be-
tween Eastern and Western countries. It is possible that
the low incidence of local recurrence in Eastern studies is
due to the extensive use of D2 lymph-node dissection.
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undergoing radical gastrectomy. Therefore, it is important
to identify patients at a high risk of recurrence. In this
study, univariate analysis showed that Borrmann type,
depth of invasion, and lymph node status were associated
with overall recurrence. Logistic regression demonstrated
that depth of invasion and lymph node metastases were
independent risk factors for overall recurrence. Consistent
with our findings, previous studies have showed that trad-
itional clinicopathological factors such as serosal exposure,
histological type, depth of invasion, and lymph node me-
tastasis were risk factors for recurrence [17-19]. However,
traditional clinicopathological factors are sometimes inad-
equate for prediction of recurrence. A number of studies
have indicated that biomarkers, such as tumor markers
[20,21], vascular endothelial growth factor (VEGF) family
[22,23], E-cadherin [24,25], and microRNAs [26], might
be useful for predicting recurrence of gastric cancer. Bcl-2
located at chromosome 18q21, and encodes a 26-kDa
protein localized mainly in the mitochondrial membrane
[27]. The bcl-2 gene was first described as an oncogene in
follicular lymphoma. Some studies have shown that overex-
pression of bcl-2 suppressed cellular proliferation and was
associated with less aggressive biological behaviour [28,29].
However, the value of bcl-2 in predicting gastric cancer re-
currences is still unclear. In a previous study, we found that
bcl-2 was significantly associated with prognosis in gastric
cancer patients [7]. Therefore, we hypothesized that bcl-2
might reflect the biological nature of the tumor, and would
serve as a reliable indicator for predicting recurrence.
According to our results, the negative expression of bcl-2 is
an independent risk factor for gastric cancer recurrence.
The exact mechanism is still unclear. It is possible that bcl-
2 affects gastric cancer recurrence by regulating the tumor
cell biological behaviour. Saegusa et al. [28] reported that
the majority of bcl-2+ cancer cells are in a nonproliferative
state, and the average expression of Ki-67 labeling index
and apoptotic labeling index in bcl-2+ foci are significantly
lower than that in bcl-2 foci. Aizawa et al. [30] showed that
the expression of bcl-2 in advanced gastric cancer is associ-
ated with a lower apoptotic index and a better prognosis.
Pietenpol et al. [31] reported that over-expression of bcl-2
inhibits the growth of several solid-tumor cell lines.
Conclusion
In conclusion, the present study demonstrated that periton-
eal recurrence was the most common recurrence pattern
after curative gastrectomy. Depth of invasion, lymph node
metastases, and negative expression of bcl-2 predict greater
risk of recurrence. These findings may provide some useful
information for followup in gastric cancer patients who
have undergone surgery for resection. Specifically, it is ne-
cessary to conduct an intensive follow-up plan for gastric
cancer patients with negative expression of bcl-2. However,the small scale and the retrospective design were short-
comings of the current study. Further large-scale, pro-
spective studies should be performed to validate the
usefulness of bcl-2 in detecting tumor recurrence in
patients with gastric cancer.
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